JAGX - Jaguar Health, Inc.
| Previous Close | 1.3300 |
| Open | 1.3400 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1200 |
| Day's Range | 1.2600 - 1.4000 |
| 52 Week Range | 1.0000 - 175.0000 |
| Volume | 1,174,936 |
| Avg. Volume | 920,196 |
| Market Cap | 8.115M |
| Beta (3Y Monthly) | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -79.4530 |
| Earnings Date | Aug 14, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
- ACCESSWIRE
Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel
SAN FRANCISCO, CA / ACCESSWIRE / September 9, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”) announced today that the Company has promoted Jonathan Wolin, an accomplished healthcare and biotech executive, to the expanded role of chief of staff, chief compliance officer and general counsel. “We are thrilled to have Jon take on this important and expanded role as part of Jaguar's management team.
- ACCESSWIRE
Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs
SAN FRANCISCO, CA / ACCESSWIRE / August 26, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”) announced today that the Company is scheduled to meet with the U.S. Food & Drug Administration’s Center for Veterinary Medicine (CVM) on September 11, 2019 to conduct a pre-submission conference about the Company’s plans to evaluate crofelemer for exercise-induced diarrhea (EID) in dogs. To expedite the submission and application process for the EID indication, Jaguar will be leveraging use of the same four major technical sections for EID that have been or will be submitted in support of the Company’s application for crofelemer delayed-release tablets (Canalevia™) for the indication of chemotherapy-induced diarrhea (CID) in dogs, which is proceeding on a parallel development path in support of conditional approval.
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern
SAN FRANCISCO, CA / ACCESSWIRE / August 22, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), today announced that the Company’s wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), is hosting a Facebook Live conversation at 3 p.m. Eastern tomorrow, August 23, 2019, between Josh Robbins and Kamaria Laffrey, a prominent HIV advocate, speaker and consultant. The discussion is part of Napo’s “HIV Community Conversations” series and can be viewed on Napo's Facebook page: facebook.com/napopharma.
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals Appoints Brian Sutton National Business Director
SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company’s wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), has promoted Brian Sutton to the role of national business director for Napo. “From a sales strategy perspective, our core focus at Napo is now on what we call ‘super targets’.
- InvestorPlace
Stock Market Today: Baidu and Sina Lead a Recovery of Chinese Stocks
It was a message meant to warn investors that stocks were in jeopardy. But, as has been the case for months now, investors ignored the warning.The message in question came from Morgan Stanley's chief United States equity strategist Mike Wilson, who noted on Monday that "The puts have expired." In other words, "With the Fed's first rate cut in a decade not having the desired effect on markets and a trade deal looking less likely every week, these two puts (the Fed and Trade Deal) may have expired, leaving investors facing the potential reality there is no second half rebound coming."InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe market may have shrugged off the warning and sent the S&P 500 up to the tune of 1.3%, on the heels of comments from Commerce Secretary Wilbur Ross. The country's chief business development leader explained in a Fox Business news interview that the government had extended a temporary license allowing an otherwise-banned Huawei to do business with U.S. partners.The added 90 days not only gives its American customers time to make alternative arrangements, but tacitly suggests the current administration is becoming more flexible on trade matters. The Nasdaq Composite outpaced the S&P 500, rallying 1.4% in response to the easing trade tensions with China. * 7 Safe Dividend Stocks for Investors to Buy Right Now The unwinding of last week's inversion of the bond yield curve may have played a role in re-inflating confidence as well. Top News in the Stock Market TodayPG&E Corporation (NYSE:PCG) isn't out of the woods yet, it seems. Shares of the utility company implicated in last year's California wildfires had been on the mend. PCG hit bottom in January, when it appeared regulators and lawyers weren't looking to destroy it. Last Friday, however, a U.S. bankruptcy judge determined that an $18 billion suit against the company for damages and death could proceed after all, even during bankruptcy proceedings. The news sent PCG stock down by 25% today.Sina (NASDAQ:SINA) rallied 15% on Monday, after reporting earnings of 73 cents per share on revenue of $533.1 million. Analysts were only calling for a top line of $510.2 million and earnings of 47 cents per share.The move would inspire other Chinese stocks higher, boosted by hope for repaired trade relations. Weibo (NASDAQ:WB) was one of them. Compared to Twitter (NYSE:TWTR), WB stock jumped 14% on Monday in step with other Chinese names after posting a solid second-quarter earnings beat of its own.Bio-pharma name Jaguar Health (NASDAQ:JAGX) reported on Monday that its Crofelemer had proven effective as a means of controlling diarrhea in dogs that had been dosed with tyrosine kinase inhibitor. Tyrosine kinase inhibitors are a means of fighting cancer in human patients, but they can cause dire side effects. Jaguar Health hopes to use Crofelemer in human clinical investigations in the future. Big MoversA relatively obscure Zscaler (NASDAQ:ZS) took center stage on Monday, falling 11% after OTR Global downgraded the cybersecurity name. Over the course of the past 12 months ZS shares had doubled in value. This made the stock an easy profit-taking target.Bouyed by Sina, Chinese stocks also bounced on possibly improving trade ties with the United States as well. However, it was stocks of companies that digitally serve Chinese consumers that led the way. Iqiyi (NASDAQ:IQ), sometimes referred to as the Netflix (NASDAQ:NFLX) of China, gained more than 6% headed into its post-close earnings report that had some investors hopeful.Baidu (NASDAQ:BIDU) was up more than 8% in front of its earnings report slated for release after the closing bell rang as well.As of the time of this writing, James Brumley did not hold a position in any of the aforementioned securities. To learn more about James, visit his site at jamesbrumley.com, or follow him on twitter at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post Stock Market Today: Baidu and Sina Lead a Recovery of Chinese Stocks appeared first on InvestorPlace.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For August 19, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. DPW Holdings (NYSE: DPW ) shares were up 261% ...
- ACCESSWIRE
Jaguar Health Achieves Statistically Significant Top Line Results in Study Evaluating Crofelemer for Treatment of Diarrhea Related to Targeted Cancer Therapy
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”) announced today that statistically significant top line results have been achieved in a key preclinical pharmacological study to evaluate the effects of crofelemer on diarrhea induced in healthy dogs by a maximally tolerated dose of a specific tyrosine kinase inhibitor (TKI) (“the Study”). The results of the Study, which was funded by a third-party cancer agent manufacturer of an FDA-approved TKI, are expected to provide additional scientific rationale and support for the use of crofelemer in providing symptomatic relief of noninfectious diarrhea in human patients receiving TKI-and/or-other targeted cancer therapy-containing regimens in future human clinical investigations.
- ACCESSWIRE
Jaguar Health Appoints Carol Lizak Chief Accounting Officer
SAN FRANCISCO, CA / ACCESSWIRE / August 16, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has promoted Carol Lizak to the role of chief accounting officer for Jaguar. Lizak formerly served as Jaguar’s vice president of finance and corporate controller. Lizak has 20+ years of corporate controllership and financial planning & analysis experience under U.S. GAAP & IFRS.
- Simply Wall St.
Read This Before Selling Jaguar Health, Inc. (NASDAQ:JAGX) Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- ACCESSWIRE
Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results
SAN FRANCISCO, CA / ACCESSWIRE / August 14, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today reported second quarter 2019 results and issued the following highlights. Mytesi Product Revenue: Mytesi net sales in the second quarter of 2019 were approximately $1.7 million, and Mytesi gross sales (non-GAAP measure) were approximately $2.4 million, an increase of 102% and 93% of net sales and gross sales, respectively, over the second quarter of 2018.
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website
SAN FRANCISCO, CA / ACCESSWIRE / August 7, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that the Company’s wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), has launched a refreshed version of the Mytesi.com website. Mytesi® is Napo’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). The website has been optimized to provide a more patient-centric user experience and help people living with HIV locate resources that can help them learn about and obtain access to Mytesi.
- ACCESSWIRE
Jaguar Health's CDMO Improves Manufacturing Processes to Support the Expanded Crofelemer Manufacturing Volume Expected to be Required for Potential Expanded Indications, Including a Potential Indication for Cancer Therapy-related Diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / August 2, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that Indena S.p.A., one of the two contract manufacturers of the active pharmaceutical ingredient (API) in crofelemer, has successfully developed and implemented an improved crofelemer manufacturing process, effectively increasing yield and realizing reduced cost through increased manufacturing efficiencies while retaining the same phytochemical profile without compromising product quality, safety, purity and efficacy. The modified process allows Jaguar's wholly-owned human-health subsidiary, Napo Pharmaceuticals, Inc., to support the increased crofelemer manufacturing demand expected if crofelemer receives FDA approval for new indications, including approval for the symptomatic relief of cancer therapy-related diarrhea (CTD).
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event at 3 p.m. Eastern Today
SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that the Company’s wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), is hosting a Facebook Live conversation at 3 p.m. Eastern time today, July 26, 2019, between Josh Robbins and Murray Penner, who serves as Executive Director, North America for the Prevention Access Campaign. The discussion can be viewed on Napo's Facebook page, facebook.com/napopharma. Prevention Access Campaign is a health equity initiative to end the dual epidemics of HIV and HIV-related stigma by empowering people with and vulnerable to HIV with accurate and meaningful information about their social, sexual, and reproductive health.
- ACCESSWIRE
Jaguar Health Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the closing of an underwritten public offering of units for gross proceeds of $16.56 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Jaguar. Proceeds from the offering will be used to fund advancement of the Company’s pipeline and business development activities, repay outstanding debt and for working capital and other general corporate purposes.
- ACCESSWIRE
Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering
SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $14.4 million before deducting underwriting discounts and commissions and offering expenses payable by Jaguar. The Series 1 Warrants and Series 2 Warrants (together, the “warrants”) will have an exercise price of $2.00 and will be exercisable upon issuance.
- ACCESSWIRE
Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million
SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the "Merger") from approximately $10.5 million (the "Original Debt") to approximately $4.4 million, thereby strengthening the Company's balance sheet. The Company accomplished this reduction in indebtedness through the issuance of approximately 1,119,440 shares of common stock, at a weighted average price of approximately $5.58 per share, to Chicago Venture Partners L.P. ("CVP") pursuant to exchange agreements entered into between the Company and CVP from May 29, 2019 through July 12, 2019.
- ACCESSWIRE
Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / July 11, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that its wholly owned subsidiary, Napo Pharmaceuticals, Inc., has agreed in principal to support a U.S.-based University’s request to begin an - Institution Initiated Clinical Research Study. The University will perform a pilot study to evaluate the safety and effectiveness of crofelemer for treatment of chronic idiopathic diarrhea in non-HIV patients (the “Study”). The Study has received approval from the University’s Institutional Review Board, and Napo Pharmaceuticals, Inc. is currently negotiating the definitive agreement with the University.
- ACCESSWIRE
Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million
SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the "Merger") from approximately $10.5 million (the "Original Debt") to approximately $5.7 million, thereby strengthening the Company's balance sheet. The Company accomplished this reduction in indebtedness through the issuance of approximately 754,838 shares of common stock, at a weighted average price of approximately $6.42 per share, to Chicago Venture Partners L.P. ("CVP") pursuant to exchange agreements entered into between the Company and CVP from May 29, 2019 through June 27, 2019.
- ACCESSWIRE
Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome
SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has entered into a Master Services Agreement ("the Agreement") with Integrium, LLC, a clinical research organization that designs, conducts, and analyzes clinical trials. Under the terms of the Agreement and the associated service order, Intergrium will provide clinical development services to Jaguar's wholly-owned human-health subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), in support of a study to evaluate the effect of Mytesi® on the gastrointestinal microbiome in people living with HIV (PLWH).
- Benzinga
The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...
- ACCESSWIRE
Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards
SAN FRANCISCO, CA / ACCESSWIRE / June 24, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it received a letter from The Nasdaq Stock Market Inc. on June 21, 2019 confirming that the bid price deficiency of Jaguar has been cured, and that the Company is in compliance with all applicable listing standards.
- ACCESSWIRE
Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs
SAN FRANCISCO, CA / ACCESSWIRE / June 19, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Target Animal Safety Technical Section of the Company's application for conditional approval of Canalevia™ for chemotherapy-induced diarrhea (CID) in dogs is expected to be submitted to the U.S. Food & Drug Administration's Center for Veterinary Medicine (CVM) in the third quarter of 2019. This Technical Section, which is the last of the four Technical Sections Jaguar is required to file for Canalevia for the proposed CID indication, will contain data from a 2017 target animal safety study indicating that the NOAEL (no-observed-adverse-effect level) of Canalevia in dogs is approximately six times greater than previously demonstrated, and that Canalevia is also safe for use in puppies.
- ACCESSWIRE
Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors
SAN FRANCISCO, CA / ACCESSWIRE / June 18, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that a nonclinical pilot study to evaluate the severity of diarrhea caused by a specified dose of a specific tyrosine kinase inhibitor (TKI) in healthy dogs has been completed. A primary nonclinical study, expected to begin this July, will evaluate the effects of crofelemer on diarrhea induced in healthy dogs by the same TKI.
- ACCESSWIRE
Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication
SAN FRANCISCO, CA / ACCESSWIRE / June 11, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that Jaguar's wholly-owned human-health subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), will receive preclinical services from the National Institute of Allergy and Infectious Diseases ("NIAID") to support the development of lechlemer, Napo's drug product candidate for a cholera indication. Under NIAID's suite of preclinical services, NIAID-funded contractors will conduct toxicology testing for 7-day rat and dog studies.
- ACCESSWIRE
Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split
SAN FRANCISCO, CA / ACCESSWIRE / June 6, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-70 (the "Reverse Stock Split"), on Friday, June 7, 2019 (the "Effective Date"). The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on the Nasdaq Capital Market under the symbol "JAGX".
